Zhonghua nei ke za zhi · 2003
[The impact of selective cycloxygenase-2 inhibitor celexibo on the formation of cholesterol gallstone].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xiao-wei, Cai Jian-ting
Аннотация
OBJECTIVE: To determine the effects of specific cyclooxygenase-2 (COX-2) inhibitor celexibo on the formation of gallstone in rabbits by comparing both the mucosa damage and the risk of gallstone formation.
METHODS: 30 rabbits were equally divided into three groups: gallstone group (induced by high cholesterol diet HCD), celexibo group (treated with celexibo 10 mg.kg(-1).day(-1) in addition to HCD) and control group (fed with formal diet). After 7 weeks, bile was obtained for observing gallstone formation, and the morphologic changes of the mucosa were assessed under microscopy. The level of COX-2 in gallbladder mucosa in each group was estimated with immunohistochemical assay.
RESULTS: Celexibo group had lower risk to get gallstones than gallstone group (2/10 vs 9/10, P < 0.05). The degree of mucosa inflammation and level of COX-2 expression were significantly higher in gallstone group than in the other two groups (0.055 +/- 0.006 vs 0.017 +/- 0.003, P < 0.001; 0.055 +/- 0.006 vs 0.169 +/- 0.001, P < 0.001).
CONCLUSIONS: Specific COX-2 inhibitor celexibo can decrease the risk of gallstone formation. COX-2 is highly expressed in gallbladder mucosa of gallstone, which suggests that there is certain inflammatory mechanism in the cholesterol gallstone formation.
METHODS: 30 rabbits were equally divided into three groups: gallstone group (induced by high cholesterol diet HCD), celexibo group (treated with celexibo 10 mg.kg(-1).day(-1) in addition to HCD) and control group (fed with formal diet). After 7 weeks, bile was obtained for observing gallstone formation, and the morphologic changes of the mucosa were assessed under microscopy. The level of COX-2 in gallbladder mucosa in each group was estimated with immunohistochemical assay.
RESULTS: Celexibo group had lower risk to get gallstones than gallstone group (2/10 vs 9/10, P < 0.05). The degree of mucosa inflammation and level of COX-2 expression were significantly higher in gallstone group than in the other two groups (0.055 +/- 0.006 vs 0.017 +/- 0.003, P < 0.001; 0.055 +/- 0.006 vs 0.169 +/- 0.001, P < 0.001).
CONCLUSIONS: Specific COX-2 inhibitor celexibo can decrease the risk of gallstone formation. COX-2 is highly expressed in gallbladder mucosa of gallstone, which suggests that there is certain inflammatory mechanism in the cholesterol gallstone formation.